Skip to main content

Research Repository

Advanced Search

All Outputs (9)

Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer (2016)
Journal Article
Rakha, E. A., Agarwal, D., Green, A. R., Ashankyty, I., Ellis, I. O., Ball, G., & Alaskandarany, M. A. (2017). Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer. Histopathology, 70(4), 622-631. https://doi.org/10.1111/his.13108

Aims Multigene assay is recommended currently for prognostic stratification of the clinically indeterminate group of breast cancer (BC) patients defined as lymph node (LN)‐negative, oestrogen receptor (ER)‐positive, HER2‐negative (LN−/ER+/HER2−) t... Read More about Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer.

Molecular classification of breast cancer: what the pathologist needs to know (2016)
Journal Article
Rakha, E. A., & Green, A. R. (2017). Molecular classification of breast cancer: what the pathologist needs to know. Pathology, 49(2), 111-119. https://doi.org/10.1016/j.pathol.2016.10.012

Breast cancer is a heterogeneous disease featuring distinct histological, molecular and clinical phenotypes. Although traditional classification systems utilising clinicopathological and few molecular markers are well established and validated, they... Read More about Molecular classification of breast cancer: what the pathologist needs to know.

Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins? (2016)
Journal Article
Toss, M. S., Pinder, S. E., Green, A. R., Thomas, J., Morgan, D. A., Robertson, J. F., …Rakha, E. A. (2017). Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?. Histopathology, 70(5), 681-692. https://doi.org/10.1111/his.13116

The introduction of mammographic screening has resulted in a rise in the detection rate of ductal carcinoma in situ (DCIS), currently accounting for one‐fifth of screen‐detected breast cancers. Although 60–70% of DCIS are treated with breast‐conservi... Read More about Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?.

Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer (2016)
Journal Article
Besusparis, J., Plancoulaine, B., Rasmusson, A., Augulis, R., Green, A. R., Ellis, I. O., …Laurinavicius, A. (2016). Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer. Diagnostic Pathology, 11(1), Article 82. https://doi.org/10.1186/s13000-016-0525-z

Background: Gene expression studies have identified molecular subtypes of breast cancer with implications to chemotherapy recommendations. For distinction of these types, a combination of immunohistochemistry (IHC) markers, including proliferative ac... Read More about Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer.

Overexpression of specific CD44 isoforms is associated with aggressive cell features in acquired endocrine resistance (2016)
Journal Article
Bellerby, R., Smith, C., Kyme, S., Gee, J., Günthert, U., Green, A., …Hiscox, S. (2016). Overexpression of specific CD44 isoforms is associated with aggressive cell features in acquired endocrine resistance. Frontiers in Oncology, 6, Article 145. https://doi.org/10.3389/fonc.2016.00145

While endocrine therapy is the mainstay of ER+ breast cancer, the clinical effectiveness of these agents is limited by the phenomenon of acquired resistance that is associated with disease relapse and poor prognosis. Our previous studies revealed tha... Read More about Overexpression of specific CD44 isoforms is associated with aggressive cell features in acquired endocrine resistance.

SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis (2016)
Journal Article
Abdel-Fatah, T. M., Agarwal, D., Liu, D.-X., Russell, R., Rueda, O. M., Liu, K., …Chan, S. Y. (2016). SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. Lancet Oncology, 17(7), 1004-1018. https://doi.org/10.1016/S1470-2045%2816%2900174-1

Background: Proliferation markers and profiles have been recommended for guiding the choice of systemic treatments for breast cancer. However, the best molecular marker or test to use has not yet been identified. We did this study to identify factors... Read More about SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes (2016)
Journal Article
Pereira, B., Chin, S.-F., Rueda, O. M., Vollan, H.-K. M., Provenzano, E., Bardwell, H. A., …Caldas, C. (in press). The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nature Communications, 7, Article 11479. https://doi.org/10.1038/ncomms11479

The genomic landscape of breast cancer is complex, and inter- and intra-tumour heterogeneity are important challenges in treating the disease. In this study, we sequence 173 genes in 2,433 primary breast tumours that have copy number aberration (CNA)... Read More about The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours (2016)
Journal Article
Green, A. R., Aleskandarany, M. A., Agarwal, D., Elsheikh, S., Nolan, C. C., Diez-Rodriguez, M., …Rakha, E. A. (2016). MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. British Journal of Cancer, 114(8), 917-928. https://doi.org/10.1038/bjc.2016.46

Background: MYC is amplified in approximately 15% of breast cancers (BCs) and is associated with poor outcome. c-MYC protein is multi-faceted and participates in many aspects of cellular function and is linked with therapeutic response in BCs. We... Read More about MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.